Abstract:Alternative routes of administration are one approach that could be used to bypass the blood–brain barrier (BBB) for effective drug delivery to the central nervous system (CNS). Here, we focused on intranasal delivery of polymer nanoparticles. We hypothesized that surface modification of poly(lactic-co-glycolic acid) (PLGA) nanoparticles with rabies virus glycoprotein (RVG29) would increase residence time and exposure of encapsulated payload to the CNS compared to non-targeted nanoparticles. Delivery kinetics and biodistribution were analyzed by administering nanoparticles loaded with the carbocyanine dye 1,1′-Dioctadecyl-3,3,3′,3′-Tetramethylindotricarbocyanine Iodide (DiR) to healthy mice. Intranasal administration yielded minimal exposure of nanoparticle payload to most peripheral organs and rapid, effective delivery to whole brain. Regional analysis of payload delivery within the CNS revealed higher delivery to tissues closest to the trigeminal nerve, including the olfactory bulb, striatum, midbrain, brainstem, and cervical spinal cord. RVG29 surface modifications presented modest targeting benefits to the striatum, midbrain, and brainstem 2 h after administration, although targeting was not observed 30 min or 6 h after administration. Payload delivery to the trigeminal nerve was 3.5× higher for targeted nanoparticles compared to control nanoparticles 2 h after nanoparticle administration. These data support a nose-to-brain mechanism of drug delivery that closely implicates the trigeminal nerve for payload delivery from nanoparticles via transport of intact nanoparticles and eventual diffusion of payload. Olfactory and CSF routes are also observed to play a role. These data advance the utility of targeted nanoparticles for nose-to-brain drug delivery of lipophilic payloads and provide mechanistic insight to engineer effective delivery vectors to treat disease in the CNS.

Targeted Delivery of Proteins into the Central Nervous System Mediated by Rabies Virus Glycoprotein-Derived Peptide

Targeted Transport of Nanocarriers into Brain for Theranosis with Rabies Virus Glycoprotein-Derived Peptide

New Brain Delivery Vector: Rabies Virus Glycoprotein-derived Peptide

Targeted Delivery of Large Fusion Protein into Hippocampal Neurons by Systemic Administration.

Advances of polypeptide fragment of rabiesvirus glycoprotein as a brain-targeting carrier

Application Progress Of Rvg Peptides To Facilitate The Delivery Of Therapeutic Agents Into The Central Nervous System

Brain-targeting Gene Delivery and Cellular Internalization Mechanisms for Modified Rabies Virus Glycoprotein RVG29 Nanoparticles.

Cell Surface Display of Rabies Virus Glycoprotein by Using Ice Nucleation Protein

Cellular Uptake Mechanism and Therapeutic Utility of a Novel Peptide in Targeted-Delivery of Proteins into Neuronal Cells

Targeting Small Molecule Delivery to the Brain and Spinal Cord via Intranasal Administration of Rabies Virus Glycoprotein (RVG29)-Modified PLGA Nanoparticles

Production and Characterization of a Fusion Peptide Derived from the Rabies Virus Glycoprotein (RVG29).

A Novel Peptide Delivers Plasmids Across Blood-Brain Barrier Into Neuronal Cells As A Single-Component Transfer Vector

A Blood-Brain Barrier Crossing Peptide

Targeting Cerebral Diseases with Enhanced Delivery of Therapeutic Proteins Across the Blood-Brain Barrier

Targeted axonal import (TAxI) peptide delivers functional proteins into spinal cord motor neurons after peripheral administration

[Targeted Inhibition of Rabies Virus Gene Expression by a Chimeric Multidomain Protein Mediated Shrna Delivery].

LRP-1-mediated Intracellular Antibody Delivery to the Central Nervous System

Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles.

RVG-peptide-linked trimethylated chitosan for delivery of siRNA to the brain.

Rabies virus-mimicking liposomes for targeted gene therapy in Alzheimer's disease

RVG Peptide-Functionalized Favipiravir Nanoparticle Delivery System Facilitates Antiviral Therapy of Neurotropic Virus Infection in a Mouse Model.